Global Autoinjectors Market by Usability, Route of Administration, Type of Molecule Delivered, Type of Actuation Mechanism, Volume of Container, End-user, Target Indication and Key Geographical Regions

As per Roots Analysis, the global autoinjectors market is estimated to grow from USD 90.6 billion in the current year to USD 175.9 billion by 2035, at a CAGR of 6.2% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Usability

Disposable
Reusable

Route of Administration

Subcutaneous
Intravenous
Intramuscular

Type of Molecule Delivered

Antibodies
Peptides
Proteins
Small Molecules
Others

Type of Actuation Mechanism

Manual
Automatic

Volume of Container

Less than 1 mL
1-2 mL
More than 2 mL

End-user

Ambulatory Surgical Centers
Home Care
Hospitals and Clinics

Target Indication

Anaphylaxis
Diabetes
Migraine
Multiple Sclerosis
Rheumatoid Arthritis
Weight Loss
Others

Key Geographical Regions

North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America

GLOBAL AUTOINJECTORS MARKET (5TH EDITION): GROWTH AND TRENDS

The global rise in chronic diseases, such as diabetes, multiple sclerosis, rheumatoid arthritis and severe allergies, has driven a pressing requirement for a more efficient, innovative and user-friendly drug delivery systems. It is worth highlighting that the impact of these chronic conditions on patients is substantial, as the associated costs and complications can escalate dramatically over a period. As a result, the medical industry has made significant efforts in developing novel drug delivery devices, including autoinjectors.

Autoinjectors are automatic injection devices that are used for the delivery of drugs through the subcutaneous or intramuscular routes. These are primarily spring-driven devices that use prefilled syringes or cartridges as primary containers. By complete or partial automation of the drug delivery process, these devices make the dosing process more convenient. Owing to which, autoinjectors have demonstrated significant potential as the next generation of patient-centric devices, capable of safe and reliable delivery of injectables. Further, the advent of novel biologics is driving the demand for injection of higher viscosities of drugs in larger volumes. Consequently, many device manufacturers, such as BD Medical and SHL, have introduced large volume autoinjectors. Additionally, the new autoinjector devices, which are currently under development, are capable of addressing the specific needs and wants of individual patients. These are designed to enable adjustments in the dosage or features of the device based upon the requirements of the user. In fact, connecting the injectors digitally to various products and platforms is expected to improve adherence and quality of life for the patients. Given these advancements in autoinjectors, the growing need for effective drug delivery systems and disease management can be efficiently addressed in the future.

GLOBAL AUTOINJECTORS MARKET: KEY INSIGHTS

The report delves into the current state of the global autoinjectors market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently, close to 150 autoinjectors are available / being manufactured by various players, globally; the majority of the autoinjector manufacturers are headquartered in North America.

2. Most of the commercially available autoinjectors are suitable for subcutaneous administration; these autoinjectors are integrated with audible and visual indicators and can deliver a myriad of molecules.

3. More than 50% of the deals in the autoinjectors domain were inked in the last three years; further, most of the intercontinental as well as intracontinental partnerships have been signed by players based in Europe.

4. Since 2019, more than 1,100 patents related to autoinjectors have been filed by / granted to various stakeholders to protect the intellectual property generated within this domain.

5. Several scientists, clinicians and industry veterans, affiliated to academic / medical / commercial organizations, are spearheading research related to autoinjectors.

6. Nearly 160 autoinjector combination products (with different drugs) have been approved by regulatory authorities, across the world; further, close to 60% of autoinjector combination product developers are very large players.

7. Around 75% of the commercialized autoinjector combination products are compatible with syringes; notably, majority of these combination products are intended to be used in homecare settings by adults.

8. More than 70 autoinjector combination products intended for the treatment of various indications are currently being evaluated in early and late stages of development; further, most of the developers for these products are publicly listed companies.

9. Around 90% of the early and late-stage combination products are currently in different clinical phases of development; majority of these are being developed for the treatment of chronic conditions (primarily rheumatoid arthritis).

10. The autoinjectors market is anticipated to grow at a steady rate; notably, disposable autoinjectors are likely to capture over 88% market share in 2024 as they eliminate the need for manual loading of medication and have lower risk of contamination.

11. Autoinjectors with automatic actuation mechanism are anticipated to grow at faster pace (~7%) till 2035; further, the autoinjectors intended for delivering drugs targeting rheumatoid arthritis are likely to dominate the current market.

12. The autoinjectors suitable for home care are likely to capture majority share in the market during the forecasted period; Asia-Pacific is anticipated to grow at higher rate in this domain, till 2035.

GLOBAL AUTOINJECTORS MARKET (5TH EDITION): KEY SEGMENTS

Disposable Autoinjectors Occupies the Largest Share of the Global Autoinjectors Market

Based on the usability, the market is segmented into disposable autoinjectors and reusable autoinjectors. At present, disposable autoinjectors segment hold the maximum share of the global autoinjectors market. This trend is likely to remain the same in the forthcoming years.

Autoinjectors for Intravenous Drug Delivery is the Fastest Growing Segment of the Global Autoinjectors Market During the Forecast Period

Based on the route of administration, the market is segmented into subcutaneous, intramuscular and intravenous routes. Currently, autoinjectors used for subcutaneous drug delivery capture the highest proportion of the global autoinjectors market. It is worth highlighting that the global autoinjector market for intravenous autoinjector segment is likely to grow at a relatively higher CAGR.

Proteins Segment Occupy the Largest Share of the Global Autoinjectors Market by Type of Molecule Delivered

Based on the type of molecule delivered, the market is segmented into antibodies, peptides, proteins, small molecules and others. At present, autoinjectors designed for the delivery of proteins hold the maximum share of the global autoinjectors market. This trend is likely to change in the foreseeable future.

By Type of Actuation Mechanism, Autoinjectors with Automatic Actuation Mechanism is the Fastest Growing Segment of the Global Autoinjectors Market During the Forecast Period

Based on the type of actuation mechanism, the market is segmented into manual and automatic actuation mechanism based autoinjectors. At present, autoinjectors equipped with automatic actuation mechanisms capture the highest proportion of the global autoinjectors market. Further, it is worth highlighting that the global autoinjector market for automatic actuation mechanism based autoinjectors is likely to grow at a relatively higher CAGR.

Autoinjectors with Volume Containers of 1-2 mL Account for the Largest Share of the Global Autoinjectors Market

Based on the volume of containers, the market is segmented into autoinjectors with less than 1 ml, 1-2 ml and more than 2 ml storing volumes. Currently, autoinjectors with a drug storing capacity of 1-2 ml of a drug hold the maximum share of the global autoinjectors market. This trend is likely to remain the same in the coming decade.

By End-user, Home Care Segment is Likely to Dominate the Global Autoinjectors Market

Based on the end-user, the market is segmented into home care, hospitals and clinics and ambulatory surgical centers. At present autoinjectors used in the home care segment hold the maximum share of the global autoinjectors market. Additionally, this segment is likely to grow at a faster pace, compared to the other segments.

Autoinjectors Designed for the Treatment of Rheumatoid Arthritis Occupy the Largest Share of the Global Autoinjectors Market

Based on the target indication, the market is segmented into anaphylaxis, diabetes, migraine, multiple sclerosis, rheumatoid arthritis, weight loss and other indications. Whilst rheumatoid arthritis target indication segment is expected to be the primary driver of the overall market, it is worth highlighting that the global autoinjectors market for weight loss segment is likely to grow at a relatively higher CAGR.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. The majority share is expected to be captured by players based in North America and Europe.

Example Players in the Global Autoinjectors Market

Amgen
Antares Pharma
ChemProtect.SK
Elcam Medical
Eli Lilly and Company
Jiangsu Delfu Medical Device
Kindeva Drug Delivery
Merck
Novartis
Novo Nordisk
Oval Medical Technologies
Owen Mumford
PreciHealth
Recipharm
Sanofi
SHL Medical
Teva Pharmaceuticals
Union Medico
Ypsomed

GLOBAL AUTOINJECTORS MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global autoinjectors market, focusing on key market segments, including [A] usability, [B] route of administration, [C] type of molecule delivered, [D] type of actuation mechanism, [E] volume of container, [F] end-user, [G] target indication and [H] key geographical regions.
Autoinjectors Market Landscape: A comprehensive evaluation of autoinjectors, considering various parameters, such as [A] status of development, [B] usability, [C] type of primary drug container, [D] requirement of needle, [E] volume of container, [F] type of dose delivered, [G] route of administration, [H] type of actuation mechanism, [I] type of feedback mechanism, [J] availability of connectivity feature, [K] target indication, [L] type of molecule delivered and [M] end-user. Additionally, a comprehensive evaluation of the companies engaged in manufacturing autoinjectors, based on several relevant parameters, such as [N] year of establishment, [O] company size (in terms of employee count), [P] location of headquarters, [Q] type of company and [R] most active players (in terms of number of autoinjectors manufactured).
Product Competitiveness Analysis: A comprehensive competitive analysis of autoinjectors, examining factors, such as [A] manufacturer strength and [B] product strength.
Brand Positioning Analysis: A comprehensive brand positioning assessment framework of the autoinjector manufacturers focusing on the current perceptions of their proprietary brands across various device types. This analysis evaluates autoinjector manufacturers by various parameters, including [A] strength and diversity of product portfolio, [B] routes of administration, [C] type of actuation mechanism, [D] type of feedback mechanism, [E] geographical presence / reach and [F] supplier strength of each player.
Company Profiles of Autoinjectors Manufacturers: In-depth profiles of key autoinjector manufacturers, focusing on [A] company overviews, [B] financial information (if available), [C] autoinjectors portfolio, [D] manufacturing capabilities and facilities, [E] recent developments and [F] an informed future outlook.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the global autoinjectors market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, [D] most active players (in terms of the number of partnerships signed) and [E] geographical distribution of partnership activity.
Patent Analysis: An in-depth analysis of patents filed / granted till date in the autoinjectors domain, based on various relevant parameters, such as [A] type of patent, [B] patent publication year, [C] patent application year, [D] patent jurisdiction, [E] CPC symbols, [F] type of applicant, [G] most active players, [H] patent benchmarking and [I] patent valuation analysis.
Commercialized Autoinjector Combination Product Market Landscape: A comprehensive evaluation of commercialized autoinjector combination products, considering various parameters, such as [A] approval year, [B] usability, [C] type of primary drug container, [D] requirement of needle, [E] volume of container, [F] injection time, [G] type of dose delivered, [H] route of administration, [I] type of actuation mechanism, [J] type of feedback mechanism, [K] availability of connectivity feature, [L] target indication, [M] severity of indication, [N] type of molecule delivered, [O] end-user and [P] target population. Additionally, a comprehensive evaluation of the companies engaged in manufacturing commercialized autoinjector combination product, based on several relevant parameters, such as [Q] year of establishment, [R] company size (in terms of employee count), [S] location of headquarters, [T] type of company and [U] most active players (in terms of number of commercialized autoinjector combination products developed).
Early and Late Stage Autoinjectors Combination Product Market Landscape: A comprehensive evaluation of early and late stage autoinjector combination products, considering various parameters, such as [A] stage of development, [B] route of administration, [C] dose strength, [D] target indication, [E] severity of indication, [F] type of molecule delivered, [G] end-user, [H] target population and [I] gender of target population. Additionally, a comprehensive evaluation of the companies engaged in manufacturing early and late stage autoinjector combination products, based on several relevant parameters, such as [J] year of establishment, [K] company size (in terms of employee count), [L] location of headquarters and [M] type of company.
Short Company Profiles of Autoinjector Combination Product Manufacturers: Short profiles of key autoinjector combination product manufacturers, focusing on [A] company overviews and [B] autoinjector product portfolio.
Key Opinion Leaders (KOLs]: An in-depth analysis that emphasizes the key opinion leaders in this domain, considering various parameters, such as [A] role of KOL, [B] type of sponsor organization, [C] affiliated organization, [D] target indication, [E] location of clinical trials and [F] most prominent KOLs.
Case Study 1: A general discussion on most commonly targeted indications, providing information on approved autoinjector combination products.
Case Study 2: A general discussion on the role of medical device CMOs in the manufacturing and assembly of drug-delivery devices, including autoinjectors, based on several relevant parameters, such as [A] scale of operation and [B] types of services provided for production of devices.
Case Study 3: A detailed assessment of prefilled syringes that are either commercialized or under development based on several relevant parameters, such as [A] type of barrel fabrication material, [B] number of barrel chambers, [C] type of needle system. In addition, the chapter provides a detailed analysis of prefilled syringe manufacturers, based on various parameters, such as [D] year of establishment, [E] company size (in terms of employee count) and [F] location of headquarters.
SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of autoinjectors market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100305

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Marget Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentation
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3.ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Future Estimates
- 3.2.2. Currency Coverage and Foreign Exchange Rate
  - 3.2.2.1. Major Currencies Affecting the Market
  - 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
  - 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
  - 3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
- 3.2.3. Trade Policies
  - 3.2.3.1. Impact of Trade Barriers on the Market
  - 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Types of Drug Delivery Systems
5.3. Drawbacks of Conventional Parenteral Delivery Systems
5.4. Emerging Trend of Self-Administration
- 5.4.1. Rising Burden of Chronic Diseases
- 5.4.2. Healthcare Cost Savings
- 5.4.3. Need for Immediate Treatment in Emergency Situations
- 5.4.4. Growth of Injectable Biologics Market
- 5.4.5. Addressing Key User Safety Requirements
5.5. Types of Self-Administration Devices
- 5.5.1. Prefilled Syringes
- 5.5.2. Pen-Injectors
- 5.5.3. Needle-Free Injectors
- 5.5.4. Large Volume Wearable Injectors
- 5.5.5. Autoinjectors
5.6. Overview of Autoinjectors
- 5.6.1. Components of Autoinjectors
- 5.6.2. Classification of Autoinjectors
  - 5.6.2.1. Classification Based on Mechanism of Action
  - 5.6.2.2. Classification Based on Usability
  - 5.6.2.3. Classification Based on Type of Dose Delivered
- 5.6.3. Manufacturing / Packaging of Autoinjectors
- 5.6.4. Benefits of Autoinjectors
5.7. Regulatory Considerations
- 5.7.1. Medical Devices
- 5.7.2. Drug Device Combination Products
5.8. Future Perspectives

6. PRIMARY DRUG CONTAINERS USED IN AUTOINJECTORS

6.1. Chapter Overview
6.2. Types of Packaging
6.3. Primary Drug Containers
- 6.3.1. Role of Primary Drug Containers
- 6.3.2. Cartridges
  - 6.3.2.1. Components of Cartridges
  - 6.3.2.2. Types of Cartridges
    - 6.3.2.2.1. Single Chamber Cartridge
    - 6.3.2.2.2. Dual Chamber Cartridge
  - 6.3.2.3. Commercially Available Cartridges
- 6.3.3. Syringes
  - 6.3.3.1. Components of Syringes
  - 6.3.3.2. Classification of Syringes
    - 6.3.3.2.1. Classification Based on Barrel Fabrication Material
    - 6.3.3.2.2. Classification Based on Number of Chambers in the Barrel
    - 6.3.3.2.3. Classification Based on Type of Needle
- 6.3.4. Vials
  - 6.3.4.1. Components of Vials
  - 6.3.4.2. Commercially Available Vials
6.4. Comparison of Different Fabrication Materials

7. AUTOINJECTORS: MARKET OVERVIEW

7.1. Chapter Overview
7.2. Autoinjectors: Overall Market Landscape
- 7.2.1. Analysis by Stage of Development
- 7.2.2. Analysis by Usability
- 7.2.3. Analysis by Type of Primary Drug Container
- 7.2.4. Analysis by Requirement of Needle
- 7.2.5. Analysis by Volume of Container
- 7.2.6. Analysis by Type of Dose Delivered
- 7.2.7. Analysis by Route of Administration
- 7.2.8. Analysis by Type of Actuation Mechanism
- 7.2.9. Analysis by Type of Feedback Mechanism
- 7.2.10. Analysis by Availability of Connectivity Feature
- 7.2.11. Analysis by Target Indication
- 7.2.12. Analysis by Type of Molecule Delivered
- 7.2.13. Analysis by End-user
7.3. Autoinjector Manufacturers: Overall Market Landscape
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters
- 7.3.4. Analysis by Company Size and Location of Headquarters
- 7.3.5. Analysis by Type of Company
- 7.3.6. Most Active Players: Analysis by Number of Autoinjectors

8. PRODUCT COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Autoinjectors: Product Competitiveness Analysis
- 8.4.1. Disposable Autoinjectors
- 8.4.2. Reusable Autoinjectors

9. BRAND POSITIONING ANALYSIS

9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Autoinjector Manufacturers: Brand Positioning Framework
- 9.4.1. Brand Positioning Framework: Owen Mumford
- 9.4.2. Brand Positioning Framework: Ypsomed
- 9.4.3. Brand Positioning Framework: Elcam Medical
- 9.4.4. Brand Positioning Framework: SHL Medical
- 9.4.5. Brand Positioning Framework: Union Medico
- 9.4.6. Brand Positioning Framework: Antares Pharma
- 9.4.7. Brand Positioning Framework: PreciHealth
- 9.4.8. Brand Positioning Framework: Jiangsu Delfu Medical Device
- 9.4.9. Brand Positioning Framework: Oval Medical Technologies
- 9.4.10. Brand Positioning Framework: Recipharm

10. AUTOINJECTOR MANUFACTURERS: DETAILED COMPANY PROFILES

10.1. Chapter Overview
10.2. Antares Pharma
- 10.2.1. Company Overview
- 10.2.2. Financial Information
- 10.2.3. Autoinjectors Portfolio
- 10.2.4 Recent Developments and Future Outlook
10.3. Elcam Medical
- 10.3.1. Company Overview
- 10.3.2. Autoinjectors Portfolio
- 10.3.3. Recent Developments and Future Outlook
10.4. Jiangsu Delfu Medical Device
- 10.4.1. Company Overview
- 10.4.2. Autoinjectors Portfolio
- 10.4.3. Recent Developments and Future Outlook
10.5. Oval Medical Technologies
- 10.5.1. Company Overview
- 10.5.2. Autoinjectors Portfolio
- 10.5.3. Recent Developments and Future Outlook
10.6. Owen Mumford
- 10.6.1. Company Overview
- 10.6.2. Autoinjectors Portfolio
- 10.6.3. Recent Developments and Future Outlook
10.7. PreciHealth
- 10.7.1. Company Overview
- 10.7.2. Autoinjectors Portfolio
- 10.7.3. Recent Developments and Future Outlook
10.8. Recipharm
- 10.8.1. Company Overview
- 10.8.2. Financial Information
- 10.8.3. Autoinjectors Portfolio
- 10.8.4. Recent Developments and Future Outlook
10.9. SHL Medical
- 10.9.1. Company Overview
- 10.9.2. Autoinjectors Portfolio
- 10.9.3. Recent Developments and Future Outlook
10.10. Union Medico
- 10.10.1. Company Overview
- 10.10.2. Autoinjectors Portfolio
- 10.10.3. Recent Developments and Future Outlook
10.11. Ypsomed
- 10.11.1. Company Overview
- 10.11.2. Financial Information
- 10.11.3. Autoinjectors Portfolio
- 10.11.4. Recent Developments and Future Outlook

11. PARTNERSHIPS AND COLLABORATIONS

11.1. Chapter Overview
11.2. Partnership Models
11.3. Autoinjectors: Partnerships and Collaborations
- 11.3.1. Analysis by Year of Partnership
- 11.3.2. Analysis by Type of Partnership
- 11.3.3. Analysis by Year and Type of Partnership
- 11.3.4. Analysis by Type of Product
- 11.3.5. Analysis by Type of Partner
- 11.3.6. Most Active Players: Analysis by Number of Partnerships
- 11.3.7. Analysis by Geography
  - 11.3.7.1. Intracontinental and Intercontinental Deals
  - 11.3.7.2. International and Local Deals

12. PATENT ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Autoinjectors: Patent Analysis
- 12.3.1. Analysis by Patent Publication Year
- 12.3.2. Analysis by Type of Patent and Patent Publication Year
- 12.3.3. Analysis by Patent Application Year
- 12.3.4. Analysis by Patent Jurisdiction
- 12.3.5. Analysis by CPC Symbols
- 12.3.6. Analysis by Type of Applicant
- 12.3.7. Leading Industry Players: Analysis by Number of Patents
- 12.3.8. Leading Individual Assignees: Analysis by Number of Patents
12.4. Patent Benchmarking Analysis
- 12.4.1. Analysis By Patent Characteristics
12.5. Patent Valuation
12.6. Leading Patents by Number of Citations

13. DRUG DEVICE COMBINATIONS: COMMERCIALIZED AUTOINJECTORS

13.1. Chapter Overview
13.2. Drug Device Combinations: Commercialized Autoinjectors
- 13.2.1. Analysis by Approval Year
- 13.2.2. Analysis by Usability
- 13.2.3. Analysis by Type of Primary Drug Container
- 13.2.4. Analysis by Requirement of Needle
- 13.2.5. Analysis by Volume of Container
- 13.2.6. Analysis by Injection Time
- 13.2.7. Analysis by Type of Dose Delivered
- 13.2.8. Analysis by Route of Administration
- 13.2.9. Analysis by Type of Actuation Mechanism
- 13.2.10. Analysis by Type of Feedback Mechanism
- 13.2.11. Analysis by Availability of Connectivity Feature
- 13.2.12. Analysis by Target Indication
- 13.2.13. Analysis by Severity of Indication
- 13.2.14. Analysis by Type of Molecule Delivered
- 13.2.15. Analysis by End-user
- 13.2.16. Analysis by Target Population
13.3. Drug Device Combinations: Commercialized Autoinjector Developers
- 13.3.1. Analysis by Year of Establishment
- 13.3.2. Analysis by Company Size
- 13.3.3. Analysis by Location of Headquarters
- 13.3.4. Analysis by Company Size and Location of Headquarters
- 13.3.5. Analysis by Type of Company
- 13.3.6. Most Active Players: Analysis by Number of Commercialized Autoinjector Combination Products

14. DRUG DEVICE COMBINATIONS: EARLY AND LATE STAGE AUTOINJECTORS

14.1. Chapter Overview
14.2. Drug Device Combinations: Early and Late Stage Autoinjectors
- 14.2.1. Analysis by Stage of Development
- 14.2.2. Analysis by Route of Administration
- 14.2.3. Analysis by Dose Strength
- 14.2.4. Analysis by Target Indication
- 14.2.5. Analysis by Severity of Indication
- 14.2.6. Analysis by Type of Molecule Delivered
- 14.2.7. Analysis by End-user
- 14.2.8. Analysis by Target Population
- 14.2.9. Analysis by Gender of Target Population
14.3. Drug Device Combinations: Early and Late Stage Autoinjector Developers Landscape
- 14.3.1. Analysis by Year of Establishment
- 14.3.2. Analysis by Company Size
- 14.3.3. Analysis by Location of Headquarters
- 14.3.4. Analysis by Company Size and Location of Headquarters
- 14.3.5. Analysis by Type of Company

15 SHORT COMPANY PROFILES: AUTOINJECTOR COMBINATION PRODUCT DEVELOPERS

15.1. Chapter Overview
15.2. Amgen
- 15.2.1. Company Overview
- 15.2.2. Autoinjector Combination Product Portfolio
15.3. ChemProtect.SK
- 15.3.1. Company Overview
- 15.3.2. Autoinjector Combination Product Portfolio
15.4. Eli Lilly and Company
- 15.4.1. Company Overview
- 15.4.2. Autoinjector Combination Product Portfolio
15.5. Kindeva Drug Delivery
- 15.5.1. Company Overview
- 15.5.2. Autoinjector Combination Product Portfolio
15.6. Merck
- 15.6.1. Company Overview
- 15.6.2. Autoinjector Combination Product Portfolio
15.7. Novartis
- 15.7.1. Company Overview
- 15.7.2. Autoinjector Combination Product Portfolio
15.8. Novo Nordisk
- 15.8.1. Company Overview
- 15.8.2. Autoinjector Combination Product Portfolio
15.9. Sanofi
- 15.9.1. Company Overview
- 15.9.2. Autoinjector Combination Product Portfolio
15.10. Teva Pharmaceutical Industries
- 15.10.1. Company Overview
- 15.10.2. Autoinjector Combination Product Portfolio

16. KEY OPINION LEADER ANALYSIS

16.1. Chapter Overview
16.2. Assumption and Key Parameters
16.3. Methodology
16.4. Autoinjectors: Key Opinion Leaders
- 16.4.1. Analysis by Role of KOL
- 16.4.2. Analysis by Type of Sponsor Organization
- 16.4.3. Analysis by Affiliated Organization
- 16.4.4. Analysis by Target Indication
- 16.4.5. Analysis by Location of Clinical Trials
- 16.4.6 Most Prominent KOLs: Analysis by Activeness, Expertise and Strength of KOL
- 16.4.7. Most Prominent KOLs: Analysis by Roots Analysis Score

17. CASE STUDY: KEY THERAPEUTIC INDICATIONS

17.1. Chapter Overview
17.2. Anaphylaxis
- 17.2.1. Overview and Epidemiology
- 17.2.2. Treatment for Anaphylaxis
- 17.2.3. Autoinjectors for Anaphylaxis
17.3. Multiple Sclerosis
- 17.3.1. Overview and Epidemiology
- 17.3.2. Treatment for Multiple Sclerosis
- 17.3.3. Autoinjectors for Multiple Sclerosis
17.4. Migraine
- 17.4.1. Overview and Epidemiology
- 17.4.2. Treatment for Migraine
- 17.4.3. Autoinjectors for Migraine
17.5. Rheumatoid Arthritis
- 17.5.1. Overview and Epidemiology
- 17.5.2. Treatment for Rheumatoid Arthritis
- 17.5.3. Autoinjectors for Rheumatoid Arthritis

18. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS

18.1. Chapter Overview
18.2. Challenges Associated with Medical Device Manufacturing
18.3. Role of CMOs in Medical Device Manufacturing
18.4. Services Offered by Medical Device CMOs
18.5. Advantages Offered by Medical Device CMOs
18.6. Risks Associated with Outsourcing to CMOs
18.7. Drug Delivery Device Service Providers
- 18.7.1. Analysis by Year of Establishment
- 18.7.2. Analysis by Company Size
- 18.7.3. Analysis by Location of Headquarters
- 18.7.4. Analysis by Type of Services
18.8. Concluding Remarks

19. CASE STUDY: PREFILLED SYRINGES

19.1. Chapter Overview
19.2. Prefilled Syringes: Market Landscape
- 19.2.1. Analysis by Type of Barrel Fabrication Material
- 19.2.2. Analysis by Number of Barrel Chambers
- 19.2.3. Analysis by Type of Needle System
19.3. Prefilled Syringes Manufacturers: Overall Market Landscape
- 19.3.1. Analysis by Year of Establishment
- 19.3.2. Analysis by Company Size
- 19.3.3. Analysis by Location of Headquarters
19.4. Future Perspectives

20. SWOT ANALYSIS

20.1. Chapter Overview
20.2. Strengths
- 20.2.1. Ease of Drug Delivery
- 20.2.2. Ability to Minimize / Eliminate Medication Errors
- 20.2.3. Enhanced Safety Features
- 20.2.4. Economic Advantages
- 20.2.5. Drug Life Cycle Management
20.3. Weaknesses
- 20.3.1. Manufacturing Complexities
- 20.3.2. Customized Design for Different Formulations
- 20.3.3. Use Errors
- 20.3.4. Stringent Regulatory Guidelines
20.4. Opportunities
- 20.4.1. Rich and Growing Pipeline of Biologics and Biosimilars
- 20.4.2. Growing Preference for Self-Injection Devices
- 20.4.3. Integration of Advanced Technologies
- 20.4.4. Rising Popularity across the Globe
20.5. Threats
- 20.5.1. Material Compatibility Issues
- 20.5.2. Availability of Alternative Drug Delivery Devices
- 20.5.3. Concern Related to Numerous Product Recalls in Past
20.6. Concluding Remarks

21. GLOBAL AUTOINJECTORS MARKET

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Global Autoinjectors Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 21.3.1. Scenario Analysis
  - 21.3.1.1. Conservative Scenario
  - 21.3.1.2 Optimistic Scenario
21.4. Key Market Segmentations

22. AUTOINJECTORS MARKET, FOR RHEUMATOID ARTHRITIS

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Autoinjectors Market for Rheumatoid Arthritis: Distribution by Usability
- 22.3.1. Disposable Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 22.3.2. Reusable Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
22.4. Autoinjectors Market for Rheumatoid Arthritis: Distribution by Route of Administration
- 22.4.1. Subcutaneous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 22.4.2. Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 22.4.3. Intravenous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
22.5. Autoinjectors Market for Rheumatoid Arthritis: Distribution by Type of Molecule Delivered
- 22.5.1. Protein-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 22.5.2. Antibody-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 22.5.3. Small Molecule-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
22.6. Leading Player

23. AUTOINJECTORS MARKET, FOR MULTIPLE SCLEROSIS

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Autoinjectors Market for Multiple Sclerosis: Distribution by Usability
- 23.3.1. Disposable Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 23.3.2. Reusable Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
23.4. Autoinjectors Market for Multiple Sclerosis: Distribution by Route of Administration
- 23.4.1. Subcutaneous Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 23.4.2. Intramuscular Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
23.5. Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule Delivered
- 23.5.1. Protein-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 23.5.2. Peptide-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 23.5.3. Antibody-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
23.6. Leading Player

24. AUTOINJECTORS MARKET, FOR DIABETES

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Autoinjectors Market for Diabetes: Distribution by Usability
- 24.3.1. Disposable Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 24.3.2. Reusable Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
24.4. Autoinjectors Market for Diabetes: Distribution by Route of Administration
- 24.4.1. Subcutaneous Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
24.5. Autoinjectors Market for Diabetes: Distribution by Type of Molecule Delivered
- 24.5.1. Protein-based Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 24.5.2. Antibody-based Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
24.6. Leading Player

25. AUTOINJECTORS MARKET, FOR WEIGHT LOSS

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Autoinjectors Market for Weight Loss: Distribution by Usability
- 25.3.1. Disposable Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
25.4. Autoinjectors Market for Weight Loss: Distribution by Route of Administration
- 25.4.1. Subcutaneous Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
25.5. Autoinjectors Market for Weight Loss: Distribution by Type of Molecule Delivered
- 25.5.1. Peptide-based Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 25.5.2. Small Molecule-based Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
25.6. Leading Player

26. AUTOINJECTORS MARKET, FOR ANAPHYLAXIS

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Autoinjectors Market for Anaphylaxis: Distribution by Usability
- 26.3.1. Disposable Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.4. Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration
- 26.4.1. Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 26.4.2. Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.5. Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule Delivered
- 26.5.1. Small Molecule-based Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.6. Leading Player

27. AUTOINJECTORS MARKET, FOR MIGRAINE

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Autoinjectors Market for Migraine: Distribution by Usability
- 27.3.1. Disposable Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.4. Autoinjectors Market for Migraine: Distribution by Route of Administration
- 27.4.1. Subcutaneous Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.5. Autoinjectors Market for Migraine: Distribution by Type of Molecule Delivered
- 27.5.1. Antibody-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 27.5.2. Protein-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 27.5.3. Small Molecule-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.6. Leading Player

28. AUTOINJECTORS MARKET, FOR OTHER INDICATIONS

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Autoinjectors Market for Other Indications: Distribution by Usability
- 28.3.1. Disposable Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 28.3.2. Reusable Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.4. Autoinjectors Market for Other Indications: Distribution by Route of Administration
- 28.4.1. Subcutaneous Autoinjectors Market for Other Indications,

Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)

28.4.2. Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.4.3. Subcutaneous / Intravenous Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)

28.5. Autoinjectors Market for Other Indications: Distribution by Type of Molecule Delivered
- 28.5.1. Antibody-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 28.5.2. Protein-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 28.5.3. Small Molecule-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 28.5.4. Other Molecule-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.6. Leading Player

29. AUTOINJECTORS MARKET, BY USABILITY

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Autoinjectors Market: Distribution by Usability
- 29.3.1. Disposable Autoinjectors Market: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 29.3.2. Reusable Autoinjectors Market: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.4. Data Triangulation and Validation

30. AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Autoinjectors Market: Distribution by Route of Administration
- 30.3.1. Autoinjectors Market for Subcutaneous Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 30.3.2. Autoinjectors Market for Subcutaneous / Intramuscular Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 30.3.3. Autoinjectors Market for Subcutaneous / Intravenous Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 30.3.4. Autoinjectors Market for Intramuscular Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 30.3.5. Autoinjectors Market for Intravenous Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
30.4. Data Triangulation and Validation

31. AUTOINJECTORS MARKET, BY TYPE OF MOLECULE DELIVERED

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Autoinjectors Market: Distribution by Type of Molecule Delivered
- 31.3.1. Autoinjectors Market for Proteins: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 31.3.2. Autoinjectors Market for Antibodies: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 31.3.3. Autoinjectors Market for Small Molecules: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 31.3.4. Autoinjectors Market for Peptides: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 31.3.5. Autoinjectors Market for Other Molecules: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
31.4. Data Triangulation and Validation

32. AUTOINJECTORS MARKET, BY TYPE OF ACTUTATION MECHANISM

32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Autoinjectors Market: Distribution by Type of Actuation Mechanism
- 32.3.1. Autoinjectors Market for Manual Actuation: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 32.3.2. Autoinjectors Market for Automatic Actuation: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
32.4. Data Triangulation and Validation

33. AUTOINJECTORS MARKET, BY VOLUME OF CONTAINER

33.1. Chapter Overview
33.2. Key Assumptions and Methodology
33.3. Autoinjectors Market: Distribution by Volume of Container
- 33.3.1. Autoinjectors Market for Containers with Less than 1 mL Volume: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 33.3.2. Autoinjectors Market for Containers with 1- 2 mL Volume: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 33.3.3. Autoinjectors Market for Containers with More than 2 mL Volume: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
33.4. Data Triangulation and Validation

34. AUTOINJECTORS, BY END-USER

34.1. Chapter Overview
34.2. Key Assumptions and Methodology
34.3. Autoinjectors Market: Distribution by End-user
- 34.3.1. Autoinjectors Market for Home Care: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 34.3.2. Autoinjectors Market for Hospitals and Clinics: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 34.3.3. Autoinjectors Market for Ambulatory Surgical Centers: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
34.4. Data Triangulation and Validation

35. AUTOINJECTORS MARKET, BY TARGET INDICATION

35.1. Chapter Overview
35.2. Key Assumptions and Methodology
35.3. Autoinjectors Market: Distribution by Target Indication
- 35.3.1. Autoinjectors Market for Rheumatoid Arthritis: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 35.3.2. Autoinjectors Market for Multiple Sclerosis: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 35.3.3 Autoinjectors Market for Diabetes: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) Data Triangulation
- 35.3.4. Autoinjectors Market for Anaphylaxis: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 35.3.5. Autoinjectors Market for Weight Loss: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 35.3.6. Autoinjectors Market for Migraine: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 35.3.7. Autoinjectors Market for Other Indications: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
35.4. Data Triangulation and Validation

36. AUTOINJECTORS, BY KEY GEOGRAPHICAL REGIONS

36.1. Chapter Overview
36.2. Key Assumptions and Methodology
36.3. Autoinjectors Market: Distribution by Key Geographical Regions
- 36.3.1. Autoinjectors Market in North America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 36.3.2. Autoinjectors Market in Europe: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 36.3.3. Autoinjectors Market in Asia-Pacific: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 36.3.4. Autoinjectors Market in Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
- 36.3.4. Autoinjectors Market in Latin America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
36.4. Data Triangulation and Validation

37. CONCLUDING REMARKS

38. EXECUTIVE INSIGHTS

38.1. Chapter Overview
38.2. Aktiv Pharma
- 38.2.1. Company Snapshot
- 38.2.2. Interview Transcript
38.3. Rx Bandz
- 38.3.1. Company Snapshot
- 38.3.2. Interview Transcript
38.4. Kindeva Drug Delivery
- 38.4.1. Company Snapshot
- 38.4.2. Interview Transcript
38.5. DALI Medical Devices
- 38.5.1. Company Snapshot
- 38.5.2. Interview Transcript:
38.6. Elcam Medical
- 38.6.1. Company Snapshot
- 38.6.2. Interview Transcript
38.7. Pharma Consult
- 38.7.1. Company Snapshot
- 38.7.2. Interview Transcript
38.8. IDEO
- 38.8.1. Company Snapshot
- 38.8.2. Interview Transcript
38.9. Bill & Melinda Gates Foundation
- 38.9.1. Company Snapshot
- 38.9.2. Interview Transcript
38.10. Oval Medical Technologies
- 38.10.1. Company Snapshot
- 38.10.2. Interview Transcript
38.11. Anonymous
38.12. Anonymous
38.13. Anonymous
38.14. Anonymous

39. APPENDIX 1: TABULATED DATA

40. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

Product Code: RA100305

List of Tables

Table 5.1 Comparison of Self-Injection Devices
Table 5.2 Benefits of Autoinjectors
Table 6.1 Commercially Available Cartridges
Table 6.2 Classification of Syringes
Table 6.3 Commercially Available Glass Syringes
Table 6.4 Commercially Available Plastic Syringes
Table 6.5 Commercially Available Vials
Table 6.6 Comparison of Fabrication Material Used for Primary Drug Containers
Table 7.1 Autoinjectors: Overall Market Landscape
Table 7.2 Autoinjectors: Information on Requirement of Needle, Volume of Container, Type of Dose Delivered and Route of Administration
Table 7.3 Autoinjectors: Information on Type of Actuation Mechanism, Type of Feedback Mechanism, Availability of Connectivity Feature and Target Indication
Table 7.4 Autoinjectors: Information on Type of Molecule Delivered and End-user
Table 7.5 Autoinjector Manufacturers: Overall Market Landscape
Table 10.1 Autoinjector Manufacturers: List of Companies Profiled
Table 10.2 Antares Pharma: Company Snapshot
Table 10.3 Antares Pharma: Autoinjectors Portfolio
Table 10.4 Halozyme (Parent Company of Antares Pharma): Recent Developments and Future Outlook
Table 10.5 Elcam Medical: Company Snapshot
Table 10.6 Elcam Medical: Autoinjectors Portfolio
Table 10.7 Jiangsu Delfu Medical Device: Company Snapshot
Table 10.8 Jiangsu Delfu Medical Device: Autoinjectors Portfolio
Table 10.9 Oval Medical Technologies: Company Snapshot
Table 10.10 Oval Medical Technologies: Autoinjectors Portfolio
Table 10.11 Oval Medical Technologies: Recent Developments and Future Outlook
Table 10.12 Owen Mumford: Company Snapshot
Table 10.13 Owen Mumford: Autoinjectors Portfolio
Table 10.14 Owen Mumford: Recent Developments and Future Outlook
Table 10.15 PreciHealth: Company Snapshot
Table 10.16 PreciHealth: Autoinjectors Portfolio
Table 10.17 PreciHealth: Recent Developments and Future Outlook
Table 10.18 Recipharm: Company Snapshot
Table 10.19 Recipharm: Autoinjectors Portfolio
Table 10.20 Recipharm: Recent Developments and Future Outlook
Table 10.21 SHL Medical: Company Snapshot
Table 10.22 SHL Medical: Autoinjectors Portfolio
Table 10.23 SHL Medical: Recent Developments and Future Outlook
Table 10.24 Union Medico: Company Snapshot
Table 10.25 Union Medico: Autoinjectors Portfolio
Table 10.26 Ypsomed: Company Snapshot
Table 10.27 Ypsomed: Autoinjectors Portfolio
Table 10.28 Ypsomed: Recent Developments and Future Outlook
Table 11.1 Autoinjectors: List of Partnerships and Collaborations, Since 2016
Table 12.1 Patent Analysis: Top CPC Sections
Table 12.2 Patent Analysis: Top CPC Symbols
Table 12.3 Patent Analysis: Top CPC Codes
Table 12.4 Patent Analysis: Summary of Benchmarking Analysis
Table 12.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 12.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 13.1 Drug Device Combinations: Commercialized Autoinjectors
Table 13.2 Commercialized Autoinjector Combination Products: Information on Requirement of Needle, Volume of Container, Injection Time and Type of Dose Delivered
Table 13.3 Commercialized Autoinjector Combination Products: Information on Route of Administration, Type of Actuation Mechanism, Type of Feedback Mechanism and
Table 13.4 Commercialized Autoinjector Combination Products: Information on Target Therapeutic Indication and Severity of Indication
Table 13.5 Commercialized Autoinjector Combination Products: Information on Type of Molecule Delivered, End-user and Target Population
Table 13.6 Commercialized Autoinjector Combination Products: List of Developers
Table 14.1 Drug Device Combinations: Early and Late Stage Autoinjectors
Table 14.2 Early and Late Stage Autoinjector Combination Products: Information on Dose Strength, Target Indication and Severity of Indication
Table 14.3 Early and Late Stage Autoinjector Combination Products: Information on Type of Molecule Delivered and End-user
Table 14.4 Early and Late Stage Autoinjector Combination Products: Information on Target Population and Gender of Target Population
Table 14.5 Early and Late Stage Autoinjector Combination Products: List of Developers
Table 15.1 Autoinjector Combination Products Developers: List of Companies Profiled
Table 15.2 Amgen: Company Snapshot
Table 15.3 Amgen: Autoinjector Combination Product Portfolio
Table 15.4 ChemProtect.SK: Company Snapshot
Table 15.5 ChemProtect.SK: Autoinjector Combination Product Portfolio
Table 15.6 Eli Lilly and Company: Company Snapshot
Table 15.7 Eli Lilly and Company: Autoinjector Combination Product Portfolio
Table 15.8 Kindeva Drug Delivery: Company Snapshot
Table 15.9 Kindeva Drug Delivery: Autoinjector Combination Product Portfolio
Table 15.10 Merck: Company Snapshot
Table 15.11 Merck: Autoinjector Combination Product Portfolio
Table 15.12 Novartis: Company Snapshot
Table 15.13 Novartis: Autoinjector Combination Product Portfolio
Table 15.14 Novo Nordisk: Company Snapshot
Table 15.15 Novo Nordisk: Autoinjector Combination Product Portfolio
Table 15.16 Sanofi: Company Snapshot
Table 15.17 Sanofi: Autoinjector Combination Product Portfolio
Table 15.18 Teva Pharmaceutical Industries: Company Snapshot
Table 15.19 Teva Pharmaceutical Industries: Autoinjector Combination Product Portfolio
Table 16.1 Autoinjectors: List of Key Opinion Leaders
Table 17.1 Anaphylaxis: Commercially Available Autoinjector Combination Products
Table 17.2 Multiple Sclerosis: Commercially Available Autoinjector Combination Products
Table 17.3 Migraine: Commercially Available Autoinjector Combination Products
Table 17.4 Rheumatoid Arthritis: Commercially Available Autoinjector Combination Products
Table 18.1 List of Medical Device CMOs Offering Services for Drug Delivery Devices
Table 18.2 Medical Device CMOs Offering Services for Drug Delivery Devices: Information on Production Services
Table 19.1 Prefilled Syringes: List of Products
Table 19.2 Prefilled Syringes: List of Manufacturers
Table 39.1 Autoinjectors: Distribution by Stage of Development
Table 39.2 Autoinjectors: Distribution by Usability
Table 39.3 Autoinjectors: Distribution by Type of Primary Drug Container
Table 39.4 Autoinjectors: Distribution by Requirement of Needle
Table 39.5 Autoinjectors: Distribution by Volume of Container
Table 39.6 Autoinjectors: Distribution by Type of Dose Delivered
Table 39.7 Autoinjectors: Distribution by Route of Administration
Table 39.8 Autoinjectors: Distribution by Type of Actuation Mechanism
Table 39.9 Autoinjectors: Distribution by Type of Feedback Mechanism
Table 39.10 Autoinjectors: Distribution by Availability of Connectivity Feature
Table 39.11 Autoinjectors: Distribution by Target Indication
Table 39.12 Autoinjectors: Distribution by Type of Molecule Delivered
Table 39.13 Autoinjectors: Distribution by End-user
Table 39.14 Autoinjector Manufacturers: Distribution by Year of Establishment
Table 39.15 Autoinjector Manufacturers: Distribution by Company Size
Table 39.16 Autoinjector Manufacturers: Distribution by Location of Headquarters (Region)
Table 39.17 Autoinjector Manufacturers: Distribution by Location of Headquarters (Country)
Table 39.18 Autoinjector Manufacturers: Distribution by Company Size and Location of Headquarters
Table 39.19 Autoinjector Manufacturers: Distribution by Type of Company
Table 39.20 Most Active Players: Distribution by Number of Autoinjectors
Table 39.21 Antares Pharma: Annual Revenues, Since FY 2017 (USD Billion)
Table 39.22 Recipharm: Annual Revenues, Since FY 2018 (SEK Billion)
Table 39.23 Ypsomed: Annual Revenues, Since FY 2018 (CHF Billion)
Table 39.24 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
Table 39.25 Partnerships and Collaborations: Distribution by Type of Partnership
Table 39.26 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 39.27 Partnerships and Collaborations: Distribution by Type of Product
Table 39.28 Partnerships and Collaborations: Distribution by Type of Partner
Table 39.29 Most Active Players: Distribution by Number of Partnerships
Table 39.90 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Table 39.31 Partnerships and Collaborations: International and Local Deals
Table 39.32 Patent Analysis: Distribution by Type of Patent
Table 39.33 Patent Analysis: Distribution by Patent Publication Year, Since 2019
Table 39.34 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 39.35 Patent Analysis: Distribution by Patent Application Year, Since Pre-2014
Table 39.36 Patent Analysis: Distribution by Patent Jurisdiction
Table 39.37 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, Since 2019
Table 39.38 Leading Industry Players: Distribution by Number of Patents
Table 39.39 Leading Individual Assignees: Distribution by Number of Patents
Table 39.40 Patent Analysis: Distribution by Patent Age
Table 39.41 Patent Analysis: Patent Valuation
Table 39.42 Commercialized Autoinjector Combination Products: Distribution by Approval Year
Table 39.43 Commercialized Autoinjector Combination Products: Distribution by Usability
Table 39.44 Commercialized Autoinjector Combination Products: Distribution by Type of Primary Drug Container
Table 39.45 Commercialized Autoinjector Combination Products: Distribution by Requirement of Needle
Table 39.46 Commercialized Autoinjector Combination Products: Distribution by Volume of Container
Table 39.47 Commercialized Autoinjector Combination Products: Distribution by Injection Time
Table 39.48 Commercialized Autoinjector Combination Products: Distribution by Type of Dose Delivered
Table 39.49 Commercialized Autoinjector Combination Products: Distribution by Route of Administration
Table 39.50 Commercialized Autoinjector Combination Products: Distribution by Type of Actuation Mechanism
Table 39.51 Commercialized Autoinjector Combination Products: Distribution by Type of Feedback Mechanism
Table 39.52 Commercialized Autoinjector Combination Products: Distribution by Availability of Connectivity Feature
Table 39.53 Commercialized Autoinjector Combination Products: Distribution by Target Indication
Table 39.54 Commercialized Autoinjector Combination Products: Distribution by Severity of Indication
Table 39.55 Commercialized Autoinjector Combination Products: Distribution by Type of Molecule Delivered
Table 39.56 Commercialized Autoinjector Combination Products: Distribution by End-user
Table 39.57 Commercialized Autoinjector Combination Products: Distribution by Target Population
Table 39.58 Commercialized Autoinjector Combination Product Developers: Distribution by Year of Establishment
Table 39.59 Commercialized Autoinjector Combination Product Developers: Distribution by Company Size
Table 39.60 Commercialized Autoinjector Combination Product Developers: Distribution by Location of Headquarters (Region)
Table 39.61 Commercialized Autoinjector Combination Product Developers: Distribution by Location of Headquarters (Country)
Table 39.62 Commercialized Autoinjector Combination Product Developers: Distribution by Company Size and Location of Headquarters
Table 39.63 Commercialized Autoinjector Combination Product Developers: Distribution by Type of Company
Table 39.64 Most Active Players: Distribution by Number of Commercialized Autoinjector Combination Products
Table 39.65 Early and Late Stage Autoinjector Combination Products: Distribution by Stage of Development
Table 39.66 Early and Late Stage Autoinjector Combination Products: Distribution by Route of Administration
Table 39.67 Early and Late Stage Autoinjector Combination Products: Distribution by Dose Strength
Table 39.68 Early and Late Stage Autoinjector Combination Products: Distribution by Target Indication
Table 39.69 Early and Late Stage Autoinjector Combination Products: Distribution by Severity of Indication
Table 39.70 Early and Late Stage Autoinjector Combination Products: Distribution by Type of Molecule Delivered
Table 39.71 Early and Late Stage Autoinjector Combination Products: Distribution by End- user
Table 39.72 Early and Late Stage Autoinjector Combination Products: Distribution by Target Population
Table 39.73 Early and Late Stage Autoinjector Combination Products: Distribution by Gender of Target Population
Table 39.74 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Year of Establishment
Table 39.75 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Company Size
Table 39.76 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Location of Headquarters
Table 39.77 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Company Size and Location of Headquarters
Table 39.78 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Type of Company
Table 39.79 KOL Analysis: Distribution by Role of KOLs
Table 39.80 KOL Analysis: Distribution by Type of Sponsor Organization
Table 39.81 KOL Analysis: Distribution by Affiliated Organization
Table 39.82 KOL Analysis: Distribution by Target Indication
Table 39.83 KOL Analysis: Distribution by Location of Clinical Trials
Table 39.84 Most Prominent KOLs: Distribution by Roots Analysis Score
Table 39.85 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Year of Establishment
Table 39.86 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Company Size
Table 39.87 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Location of Headquarters
Table 39.88 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Types of Services
Table 39.89 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Table 39.90 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 39.91 Prefilled Syringes: Distribution by Type of Needle System
Table 39.92 Prefilled Syringe Manufacturers: Distribution by Year of Establishment
Table 39.93 Prefilled Syringe Manufacturers: Distribution by Company Size
Table 39.94 Prefilled Syringe Manufacturers: Distribution by Location of Headquarters
Table 39.99 Global Autoinjectors Market, Historical Trends (Since 2018) (USD Billion)
Table 39.100 Global Autoinjectors Market, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.101 Disposable Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) (USD Billion)
Table 39.102 Disposable Autoinjectors Market for Rheumatoid Arthritis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.103 Reusable Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) (USD Billion)
Table 39.104 Reusable Autoinjectors Market for Rheumatoid Arthritis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.105 Subcutaneous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) (USD Billion)
Table 39.106 Subcutaneous Autoinjectors Market for Rheumatoid Arthritis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.107 Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) (USD Billion)
Table 39.108 Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.109 Intravenous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) (USD Billion)
Table 39.110 Intravenous Autoinjectors Market for Rheumatoid Arthritis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.111 Proteins Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) (USD Billion)
Table 39.112 Proteins Autoinjectors Market for Rheumatoid Arthritis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.113 Antibody-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) (USD Billion)
Table 39.114 Antibody-based Autoinjectors Market for Rheumatoid Arthritis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.115 Small Molecule-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) (USD Billion)
Table 39.116 Small Molecule-based Autoinjectors Market for Rheumatoid Arthritis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.117 Disposable Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) (USD Billion)
Table 39.118 Disposable Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.119 Reusable Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) (USD Billion)
Table 39.120 Reusable Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.121 Subcutaneous Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) (USD Billion)
Table 39.122 Subcutaneous Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.123 Intramuscular Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) (USD Billion)
Table 39.124 Intramuscular Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.125 Protein-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) (USD Billion)
Table 39.126 Protein-based Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.127 Peptide-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) (USD Billion)
Table 39.128 Peptide-based Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.129 Antibody-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) (USD Billion)
Table 39.130 Antibody-based Autoinjector Market for Multiple Sclerosis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.131 Disposable Autoinjectors Market for Diabetes, Historical Trends (Since 2018) (USD Billion)
Table 39.132 Disposable Autoinjectors Market for Diabetes, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.133 Reusable Autoinjectors Market for Diabetes, Historical Trends (Since 2018) (USD Billion)
Table 39.134 Reusable Autoinjectors Market for Diabetes, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.135 Subcutaneous Autoinjectors Market for Diabetes, Historical Trends (Since 2018) (USD Billion)
Table 39.136 Subcutaneous Autoinjectors Market for Diabetes, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.137 Protein-based Autoinjectors Market for Diabetes, Historical Trends (Since 2018) (USD Billion)
Table 39.138 Protein-based Autoinjectors Market for Diabetes, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.139 Antibody-based Autoinjectors Market for Diabetes, Historical Trends (Since 2018) (USD Billion)
Table 39.140 Antibody-based Autoinjectors Market for Diabetes, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.141 Disposable Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) (USD Billion)
Table 39.142 Disposable Autoinjectors Market for Anaphylaxis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.143 Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) (USD Billion)
Table 39.144 Intramuscular Autoinjectors Market for Anaphylaxis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.145 Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) (USD Billion)
Table 39.146 Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.147 Small Molecule-based Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) (USD Billion)
Table 39.148 Small Molecule-based Autoinjectors Market for Anaphylaxis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.149 Disposable Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) (USD Billion)
Table 39.150 Disposable Autoinjectors Market for Weight Loss, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.151 Subcutaneous Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) (USD Billion)
Table 39.152 Subcutaneous Autoinjectors Market for Weight Loss, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.153 Peptide-based Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) (USD Billion)
Table 39.154 Peptide-based Autoinjectors Market for Weight Loss, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.155 Small Molecule-based Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) (USD Billion)
Table 39.156 Small Molecule-based Autoinjectors Market for Anaphylaxis, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.157 Disposable Autoinjectors Market for Migraine, Historical Trends (Since 2018) (USD Billion)
Table 39.158 Disposable Autoinjectors Market for Migraine, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.159 Subcutaneous Autoinjectors Market for Migraine, Historical Trends (Since 2018) (USD Billion)
Table 39.160 Subcutaneous Autoinjectors Market for Migraine, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.161 Antibody-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) (USD Billion)
Table 39.162 Antibody-based Autoinjectors Market for Migraine, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.163 Protein-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) (USD Billion)
Table 39.164 Protein-based Autoinjectors Market for Migraine, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.165 Small Molecule-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) (USD Billion)
Table 39.166 Small Molecule-based Autoinjectors Market for Migraine, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.167 Disposable Autoinjectors Market for Other Indications, Historical Trends (Since 2018) (USD Billion)
Table 39.168 Disposable Autoinjectors Market for Other Indications, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.169 Reusable Autoinjectors Market for Other Indications, Historical Trends (Since 2018) (USD Billion)
Table 39.170 Reusable Autoinjectors Market for Other Indications, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.171 Subcutaneous Autoinjectors Market for Other Indications, Historical Trends (Since 2018) (USD Billion)
Table 39.172 Subcutaneous Autoinjectors Market for Other Indications, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.173 Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Historical Trends (Since 2018) (USD Billion)
Table 39.174 Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.175 Subcutaneous / Intravenous Autoinjectors Market for Other Indications, Historical Trends (Since 2018) (USD Billion)
Table 39.176 Subcutaneous / Intravenous Autoinjectors Market for Other Indications, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.177 Antibody-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) (USD Billion)
Table 39.178 Antibody-based Autoinjectors Market for Other Indications, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.179 Protein-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) (USD Billion)
Table 39.180 Protein-based Autoinjectors Market for Other Indications, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.181 Small Molecule-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) (USD Billion)
Table 39.182 Small Molecule-based Autoinjectors Market for Other Indications, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.183 Other Molecule-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) (USD Billion)
Table 39.184 Other Molecule-based Autoinjectors Market for Other Indications, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.185 Autoinjectors Market: Distribution by Usability
Table 39.186 Disposable Autoinjectors Market, Historical Trends (Since 2018) (USD Billion)
Table 39.187 Disposable Autoinjectors Market, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.188 Reusable Autoinjectors Market, Historical Trends (Since 2018) (USD Billion)
Table 39.189 Reusable Autoinjectors Market, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.190 Autoinjectors Market: Distribution by Route of Administration
Table 39.191 Autoinjectors Market for Subcutaneous Administration, Historical Trends (Since 2018) (USD Billion)
Table 39.192 Autoinjectors Market for Subcutaneous Administration, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.193 Autoinjectors Market for Intramuscular Administration, Historical Trends (Since 2018) (USD Billion)
Table 39.194 Autoinjectors Market for Intramuscular Administration, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.195 Autoinjectors Market for Intravenous Administration, Historical Trends (Since 2018) (USD Billion)
Table 39.196 Autoinjectors Market for Intravenous Administration t, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.197 Autoinjectors Market for Subcutaneous / Intramuscular Administration, Historical Trends (Since 2018) (USD Billion)
Table 39.198 Autoinjectors Market for Subcutaneous / Intramuscular Administration, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.199 Autoinjectors Market for Subcutaneous / Intravenous Administration, Historical Trends (Since 2018) (USD Billion)
Table 39.200 Autoinjectors Market for Subcutaneous / Intravenous Administration, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.201 Autoinjectors Market: Distribution by Type of Molecule Delivered
Table 39.202 Autoinjectors Market for Proteins, Historical Trends (Since 2018) (USD Billion)
Table 39.203 Autoinjectors Market for Proteins, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.204 Autoinjectors Market for Small Molecules, Historical Trends (Since 2018) (USD Billion)
Table 39.205 Autoinjectors Market for Small Molecules, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.206 Autoinjectors Market for Antibodies, Historical Trends (Since 2018) (USD Billion)
Table 39.207 Autoinjectors Market for Antibodies, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.208 Autoinjectors Market for Peptides, Historical Trends (Since 2018) (USD Billion)
Table 39.209 Autoinjectors Market for Peptides, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.210 Autoinjectors Market for Other Molecules, Historical Trends (Since 2018) (USD Billion)
Table 39.211 Autoinjectors Market for Other Molecules, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.212 Autoinjectors Market: Distribution by Type of Actuation Mechanism
Table 39.213 Autoinjectors Market for Manual Actuation, Historical Trends (Since 2018) (USD Billion)
Table 39.214 Autoinjectors Market for Manual Actuation, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.215 Autoinjectors Market for Automatic Actuation, Historical Trends (Since 2018) (USD Billion)
Table 39.216 Autoinjectors Market for Automatic Actuation, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.217 Autoinjectors Market: Distribution by Volume of Container
Table 39.218 Autoinjectors Market for Less than 1 mL Volume, Historical Trends (Since 2018) (USD Billion)
Table 39.219 Autoinjectors Market for Less than 1 mL Volume, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.220 Autoinjectors Market for 1-2 mL Volume, Historical Trends (Since 2018) (USD Billion)
Table 39.221 Autoinjectors Market for 1-2 mL Volume, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.222 Autoinjectors Market for More than 2 mL Volume, Historical Trends (Since 2018) (USD Billion)
Table 39.223 Autoinjectors Market for More than 2 mL Volume, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.224 Autoinjectors Market: Distribution by End-user
Table 39.225 Autoinjectors Market for Home Care, Historical Trends (Since 2018) (USD Billion)
Table 39.226 Autoinjectors Market for Home Care, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.227 Autoinjectors Market for Hospitals and Clinics, Historical Trends (Since 2018) (USD Billion)
Table 39.228 Autoinjectors Market for Hospitals and Clinics, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.229 Autoinjectors Market for Ambulatory Surgical Centers, Historical Trends (Since 2018) (USD Billion)
Table 39.230 Autoinjectors Market for Ambulatory Surgical Centers, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.231 Autoinjectors Market: Distribution by Target Indication
Table 39.232 Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) (USD Billion)
Table 39.233 Autoinjectors Market for Rheumatoid Arthritis, Forecasted Estimates (Till 2035)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Secondary Research: Data Sources
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Autoinjectors Market Overview
Figure 4.2 Executive Summary: Partnerships and Collaborations
Figure 4.3 Executive Summary: Patent Analysis
Figure 4.4 Executive Summary: Commercialized Autoinjector Combination Products Market Overview
Figure 4.5 Executive Summary: Early and Late Stage Autoinjector Combination Products Market Overview
Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Drug Delivery Systems
Figure 5.2 Types of Self-Injection Devices
Figure 5.3 Components of Autoinjector
Figure 5.4 Cartridge Based Autoinjectors versus Prefilled Syringe Based Autoinjectors
Figure 5.5 Classification of Autoinjectors
Figure 7.1 Autoinjectors: Distribution by Stage of Development
Figure 7.2 Autoinjectors: Distribution by Usability
Figure 7.3 Autoinjectors: Distribution by Type of Primary Drug Container
Figure 7.4 Autoinjectors: Distribution by Requirement of Needle
Figure 7.5 Autoinjectors: Distribution by Volume of Container
Figure 7.6 Autoinjectors: Distribution by Type of Dose Delivered
Figure 7.7 Autoinjectors: Distribution by Route of Administration
Figure 7.8 Autoinjectors: Distribution by Type of Actuation Mechanism
Figure 7.9 Autoinjectors: Distribution by Type of Feedback Mechanism
Figure 7.10 Autoinjectors: Distribution by Availability of Connectivity Feature
Figure 7.11 Autoinjectors: Distribution by Target Indication
Figure 7.12 Autoinjectors: Distribution by Type of Molecule Delivered
Figure 7.13 Autoinjectors: Distribution by End-user
Figure 7.14 Autoinjector Manufacturers: Distribution by Year of Establishment
Figure 7.15 Autoinjector Manufacturers: Distribution by Company Size
Figure 7.16 Autoinjector Manufacturers: Distribution by Location of Headquarters (Region)
Figure 7.17 Autoinjector Manufacturers: Distribution by Location of Headquarters (Country)
Figure 7.18 Autoinjector Manufacturers: Distribution by Company Size and Location of Headquarters
Figure 7.19 Autoinjector Manufacturers: Distribution by Type of Company
Figure 7.20 Most Active Players: Distribution by Number of Autoinjectors
Figure 8.1 Product Competitiveness Analysis: Disposable Autoinjectors
Figure 8.2 Product Competitiveness Analysis: Reusable Autoinjectors
Figure 9.1 Brand Positioning Analysis: Competitive Advantage
Figure 9.2 Brand Positioning Analysis: Reasons to Believe
Figure 9.3 Brand Positioning Framework: Owen Mumford
Figure 9.4 Brand Positioning Framework: Ypsomed
Figure 9.5 Brand Positioning Framework: Elcam Medical
Figure 9.6 Brand Positioning Framework: SHL Medical
Figure 9.7. Brand Positioning Framework: Union Medico
Figure 9.8 Brand Positioning Framework: Antares Pharma
Figure 9.9 Brand Positioning Framework: PreciHealth
Figure 9.10 Brand Positioning Framework: Jiangsu Delfu Medical Device
Figure 9.11 Brand Positioning Framework: Oval Medical Technologies
Figure 9.12 Brand Positioning Framework: Recipharm
Figure 10.1 Antares Pharma: Annual Revenues, Since FY 2017 (USD Billion)
Figure 10.2 Recipharm: Annual Revenues, Since FY 2018 (SEK Billion)
Figure 10.3 Ypsomed: Annual Revenues, Since FY 2018 (CHF Billion)
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2019
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 11.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.6 Most Active Players: Distribution by Number of Partnerships
Figure 11.7 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 11.8 Partnerships and Collaborations: International and Local Deals
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, Since 2019
Figure 12.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 12.4 Patent Analysis: Distribution by Patent Application Year, Since Pre-2014
Figure 12.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 12.6 Patent Analysis: Distribution by CPC Symbols
Figure 12.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, Since 2019
Figure 12.8 Leading Industry Players: Distribution by Number of Patents
Figure 12.9 Leading Individual Assignees: Distribution by Number of Patents
Figure 12.10 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (Top CPC Codes)
Figure 12.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 12.12 Patent Analysis: Distribution by Patent Age
Figure 12.13 Patent Valuation
Figure 13.1 Commercialized Autoinjector Combination Products: Distribution by Approval Year
Figure 13.2 Commercialized Autoinjector Combination Products: Distribution by Usability
Figure 13.3 Commercialized Autoinjector Combination Products: Distribution by Type of Primary Drug Container
Figure 13.4 Commercialized Autoinjector Combination Products: Distribution by Requirement of Needle
Figure 13.5 Commercialized Autoinjector Combination Products: Distribution by Volume of Container
Figure 13.6 Commercialized Autoinjector Combination Products: Distribution by Injection Time
Figure 13.7 Commercialized Autoinjector Combination Products: Distribution by Type of Dose Delivered
Figure 13.8 Commercialized Autoinjector Combination Products: Distribution by Route of Administration
Figure 13.9 Commercialized Autoinjector Combination Products: Distribution by Type of Actuation Mechanism
Figure 13.10 Commercialized Autoinjector Combination Products: Distribution by Type of Feedback Mechanism
Figure 13.11 Commercialized Autoinjector Combination Products: Distribution by Availability of Connectivity Feature
Figure 13.12 Commercialized Autoinjector Combination Products: Distribution by Target Indication
Figure 13.13 Commercialized Autoinjector Combination Products: Distribution by Severity of Indication
Figure 13.14 Commercialized Autoinjector Combination Products: Distribution by Type of Molecule Delivered
Figure 13.15 Commercialized Autoinjector Combination Products: Distribution by End-user
Figure 13.16 Commercialized Autoinjector Combination Products: Distribution by Target Population
Figure 13.17 Commercialized Autoinjector Combination Product Developers: Distribution by Year of Establishment
Figure 13.18 Commercialized Autoinjector Combination Product Developers: Distribution by Company Size
Figure 13.19 Commercialized Autoinjector Combination Product Developers: Distribution by Location of Headquarters
Figure 13.20 Commercialized Autoinjector Combination Product Developers: Distribution by Company Size and Location of
Figure 13.21 Commercialized Autoinjector Combination Product Developers: Distribution by Type of Company
Figure 13.22 Most Active Players: Distribution by Number of Commercialized Autoinjector Combination Products
Figure 14.1 Early and Late Stage Autoinjector Combination Products: Distribution by Stage of Development
Figure 14.2 Early and Late Stage Autoinjector Combination Products: Distribution by Route of Administration
Figure 14.3 Early and Late Stage Autoinjector Combination Products: Distribution by
Figure 14.4 Early and Late Stage Autoinjector Combination Products: Distribution by Target Indication
Figure 14.5 Early and Late Stage Autoinjector Combination Products: Distribution by Severity of Indication
Figure 14.6 Early and Late Stage Autoinjector Combination Products: Distribution by Type of Molecule Delivered
Figure 14.7 Early and Late Stage Autoinjector Combination Products: Distribution by End- user
Figure 14.8 Early and Late Stage Autoinjector Combination Products: Distribution by Target Population
Figure 14.9 Early and Late Stage Autoinjector Combination Products: Distribution by Gender of Target Population
Figure 14.10 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Year of Establishment
Figure 14.11 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Company Size
Figure 14.12 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Location of Headquarters
Figure 14.13 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Company Size and Location of Headquarters
Figure 14.14 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Type of Company
Figure 16.1 KOL Analysis: Distribution by Role of KOLs
Figure 16.2 KOL Analysis: Distribution by Type of Sponsor Organization
Figure 16.3 KOL Analysis: Distribution by Affiliated Organization
Figure 16.4 KOL Analysis: Distribution by Target Indication
Figure 16.5 KOL Analysis: Distribution by Location of Clinical Trials
Figure 16.6 Most Prominent KOLs: Distribution by Activeness, Expertise and Strength of KOL
Figure 16.7 Most Prominent KOLs: Distribution by Roots Analysis Score
Figure 18.1 Challenges Associated with Medical Device Manufacturing
Figure 18.2 Services Offered by Medical Device CMOs
Figure 18.3 Advantages of Outsourcing to CMOs
Figure 18.4 Risks Associated with Outsourcing to CMOs
Figure 18.5 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Year of Establishment
Figure 18.6 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Company Size
Figure 18.7 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Location of Headquarters
Figure 18.8 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Types of Services
Figure 19.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Figure 19.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 19.3 Prefilled Syringes: Distribution by Type of Needle System
Figure 19.4 Prefilled Syringe Manufacturers: Distribution by Year of Establishment
Figure 19.5 Prefilled Syringe Manufacturers: Distribution by Company Size
Figure 19.6 Prefilled Syringe Manufacturers: Distribution by Location of Headquarters
Figure 20.1 Autoinjectors: SWOT Analysis
Figure 20.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 21.1 Global Autoinjectors Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.2 Global Autoinjectors Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Figure 21.3 Global Autoinjectors Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Figure 22.1 Disposable Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.2 Reusable Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.3 Subcutaneous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.4 Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.5 Intravenous Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.6 Protein-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.7 Antibody-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.8 Small Molecule-based Autoinjectors Market for Rheumatoid Arthritis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.1 Disposable Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.2 Reusable Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.3 Subcutaneous Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.4 Intramuscular Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.5 Protein-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.6 Peptide-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.7 Antibody-based Autoinjectors Market for Multiple Sclerosis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.1 Disposable Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.2 Reusable Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.3 Subcutaneous Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.4 Protein-based Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 24.5 Antibody-based Autoinjectors Market for Diabetes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.1 Disposable Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.2 Subcutaneous Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.3 Peptide-based Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.4 Small Molecule-based Autoinjectors Market for Weight Loss, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.1 Disposable Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.2 Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.3 Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.4 Small Molecule-based Autoinjectors Market for Anaphylaxis, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.1 Disposable Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.2 Subcutaneous Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.3 Antibody-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.4 Protein-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 27.5 Small Molecule-based Autoinjectors Market for Migraine, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.1 Disposable Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.2 Reusable Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.3 Subcutaneous Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.4 Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.5 Subcutaneous / Intravenous Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.6 Antibody-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.7 Protein-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.8 Small Molecule-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.9 Other Molecule-based Autoinjectors Market for Other Indications, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.1 Autoinjectors Market: Distribution by Usability
Figure 29.2 Disposable Autoinjectors Market: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.3 Reusable Autoinjectors Market: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.1 Autoinjectors Market: Distribution by Route of Administration
Figure 30.2 Autoinjectors Market for Subcutaneous Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.3 Autoinjectors Market for Subcutaneous / Intramuscular Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.4 Autoinjectors Market for Subcutaneous / Intravenous Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.5 Autoinjectors Market for Intramuscular Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.6 Autoinjectors Market for Intravenous Administration: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.1 Autoinjectors Market: Distribution by Type of Molecule Delivered
Figure 31.2 Autoinjectors Market for Proteins: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.3 Autoinjectors Market for Antibodies: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.4 Autoinjectors Market for Small Molecules: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.5 Autoinjectors Market for Peptides: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.5 Autoinjectors Market for Other Molecules: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.1 Autoinjectors Market: Distribution by Type of Actuation Mechanism
Figure 32.2 Autoinjectors Market for Manual Actuation: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.3 Autoinjectors Market for Automatic Actuation: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 33.1 Autoinjectors Market: Distribution by Volume of Container
Figure 33.2 Autoinjectors Market for Containers of Less than 1 mL Volume: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 33.3 Autoinjectors Market for Containers of 1-2 mL Volume: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 33.4 Autoinjectors Market for Containers of More than 2 mL Volume: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 34.1 Autoinjectors Market: Distribution by End-user
Figure 34.2 Autoinjectors Market for Home Care: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 34.3 Autoinjectors Market for Hospitals and Clinics: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 34.4 Autoinjectors Market for Ambulatory Surgical Centers: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 35.1 Autoinjectors Market: Distribution by Target Indication
Figure 35.2 Autoinjectors Market for Rheumatoid Arthritis: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 35.3 Autoinjectors Market for Multiple Sclerosis: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 35.4 Autoinjectors Market for Diabetes: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 35.5 Autoinjectors Market for Anaphylaxis: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 35.6 Autoinjectors Market for Weight Loss: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 35.7 Autoinjectors Market for Migraine: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 35.8 Autoinjectors Market for Other Indications: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 36.1 Autoinjectors Market: Distribution by Key Geographical Regions
Figure 36.2 Autoinjectors Market in North America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 36.3 Autoinjectors Market in Europe: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 36.4 Autoinjectors Market in Asia-Pacific: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 36.5 Autoinjectors Market in Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 36.6 Autoinjectors Market in Latin America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 37.1 Concluding Remarks: Autoinjectors Market Overview

Figure 37.2 Concluding Remarks: Partnerships and Collaborations
Figure 37.3 Concluding Remarks: Patent Analysis

Figure 37.4 Concluding Remarks: Commercialized Autoinjector Combination Product Market Overview

Figure 37.5 Concluding Remarks: Early and Late Stage Autoinjector Combination Product Market Overview

Figure 37.6 Concluding Remarks: Market

Sizing and Opportunity Analysis

Global Autoinjectors Market by Usability, Route of Administration, Type of Molecule Delivered, Type of Actuation Mechanism, Volume of Container, End-user, Target Indication and Key Geographical Regions

Description

Table of Contents

List of Tables

GLOBAL AUTOINJECTORS MARKET (5TH EDITION): OVERVIEW

GLOBAL AUTOINJECTORS MARKET (5TH EDITION): GROWTH AND TRENDS

GLOBAL AUTOINJECTORS MARKET: KEY INSIGHTS

GLOBAL AUTOINJECTORS MARKET (5TH EDITION): KEY SEGMENTS

Example Players in the Global Autoinjectors Market

GLOBAL AUTOINJECTORS MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3.ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. PRIMARY DRUG CONTAINERS USED IN AUTOINJECTORS

7. AUTOINJECTORS: MARKET OVERVIEW

8. PRODUCT COMPETITIVENESS ANALYSIS

9. BRAND POSITIONING ANALYSIS

10. AUTOINJECTOR MANUFACTURERS: DETAILED COMPANY PROFILES

11. PARTNERSHIPS AND COLLABORATIONS

12. PATENT ANALYSIS

13. DRUG DEVICE COMBINATIONS: COMMERCIALIZED AUTOINJECTORS

14. DRUG DEVICE COMBINATIONS: EARLY AND LATE STAGE AUTOINJECTORS

15 SHORT COMPANY PROFILES: AUTOINJECTOR COMBINATION PRODUCT DEVELOPERS

16. KEY OPINION LEADER ANALYSIS

17. CASE STUDY: KEY THERAPEUTIC INDICATIONS

18. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS

19. CASE STUDY: PREFILLED SYRINGES

20. SWOT ANALYSIS

21. GLOBAL AUTOINJECTORS MARKET

22. AUTOINJECTORS MARKET, FOR RHEUMATOID ARTHRITIS

23. AUTOINJECTORS MARKET, FOR MULTIPLE SCLEROSIS

24. AUTOINJECTORS MARKET, FOR DIABETES

25. AUTOINJECTORS MARKET, FOR WEIGHT LOSS

26. AUTOINJECTORS MARKET, FOR ANAPHYLAXIS

27. AUTOINJECTORS MARKET, FOR MIGRAINE

28. AUTOINJECTORS MARKET, FOR OTHER INDICATIONS

29. AUTOINJECTORS MARKET, BY USABILITY

30. AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION

31. AUTOINJECTORS MARKET, BY TYPE OF MOLECULE DELIVERED

32. AUTOINJECTORS MARKET, BY TYPE OF ACTUTATION MECHANISM

33. AUTOINJECTORS MARKET, BY VOLUME OF CONTAINER

34. AUTOINJECTORS, BY END-USER

35. AUTOINJECTORS MARKET, BY TARGET INDICATION

36. AUTOINJECTORS, BY KEY GEOGRAPHICAL REGIONS

37. CONCLUDING REMARKS

38. EXECUTIVE INSIGHTS

39. APPENDIX 1: TABULATED DATA

40. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List of Tables

List of Figures

Figure 37.1 Concluding Remarks: Autoinjectors Market Overview

Figure 37.4 Concluding Remarks: Commercialized Autoinjector Combination Product Market Overview

Figure 37.5 Concluding Remarks: Early and Late Stage Autoinjector Combination Product Market Overview